Strategy analysis

copd-pricing-reimbursement-and-access_160221_10-2016

Chronic Obstructive Pulmonary Disease (COPD): Market Access Pricing & Reimbursement

$7,000.00

Long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) combination inhalers have been gaining traction due to an expanding evidence base for their wider use, and competitive pricing.

October 17, 2016

prostate-cancer-pricing-reimbursement-and-access_162106_10-2016

Prostate Cancer: Market Access Pricing & Reimbursement

The prostate cancer market has become saturated in the metastatic castration-resistant prostate cancer (CRPC) setting; the approval of second-generation antiandrogens, radiotherapies, and chemotherapies has resulted in a great deal of development targeting earlier stages of the disease.

June 1, 2018

Multiple Myeloma Pricing, Reimbursement, and Access

Highlights: The budget impact of multiple myeloma is set to increase While multiple myeloma represents a relatively small patient population in comparison to other cancers, payers are concerned about the rising spend on the indication. New biologic therapies are increasingly gaining label expansions in earlier treatment lines, and with life expectancies improving, patients are requiring […]

March 5, 2019

Asthma Pricing, Reimbursement, and Access

The next wave of key therapies in asthma includes biologics, with interleukin (IL)-5 inhibitors first to reach the market.

October 17, 2016

US Healthcare System Overview

Continued growth in healthcare expenditure and the high number of individuals without health insurance coverage were the key drivers of the passage of the healthcare reform law.

UK Regulatory Issues

Recently there have been several new regulatory changes in the UK aimed at reducing the regulatory burden and allowing earlier access to medicines which are seen as a positive development for the pharmaceutical industry.

Japan Regulatory Issues

Historically Japan has been plagued with delays, with new drug approvals sometimes taking three or four years longer than in the US and EU.

US Regulatory Issues

Key regulatory developments include the new Prescription Drug User Fee Act (PDUFA-V), which aims to improve interaction between the FDA and drug developers.

Mid Pharma Outlook

$3,000.00

Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth.

September 28, 2016

Breakthrough Therapy Designation: Paving the Way for Innovation

$499.00

With the passage of the FDA Safety and Innovation Act of 2012 (FDASIA), the Breakthrough Therapy Designation (BTD) was introduced as the newest mechanism to facilitate expedited development and review. Here we provide an overview of the BTD pathway and its evolution over the past three years.

April 23, 2015

Datamonitor Malignant Melanoma Pricing and Reimbursement

Malignant Melanoma Pricing, Reimbursement and Access

This strategy report focuses on Malignant Melanoma Pricing and Reimbursement including how immunotherapies are changing melanoma treatment paradigms with market conext in the US, Japan, and five major EU markets.

September 30, 2015

Biosimilars Market Access in the US

This strategy report focuses Biosimilars Market Access in the US including the need for biosimilars, regulatory pathways, substitution and naming policy, legal issues, pricing, reimbursement, and market access.

October 23, 2015

Immuno-Oncology Overview

$7,500.00

Immuno-oncology is an area of medicine that focuses on the development of therapies that improve the body’s ability to generate an immune response against cancer (Eggermont and Finn, 2012).

December 13, 2017

Accountable Care Organizations – What Impact on Pharma

$7,500.00

This strategy report focuses Accountable Care Organizations and what impact they will have on pharma including an evaluation of ACOs’ structures, sizes, cultures, and risks.

July 16, 2015